Corrigendum to article “Clotrimazole nanoemulsion for malaria chemotherapy. Part II: Stability assessment, in vivo pharmacodynamic evaluations and toxicological studies” [Int. J. Pharm. 431(1–2) (2012) 149–160] (International Journal of Pharmaceutics (2012) 431(1–2) (149–160), (S0378517311011574), (10.1016/j.ijpharm.2011.12.031));Clotrimazole nanoemulsion for malaria chemotherapy. Part II: Stability assessment, in vivo pharmacodynamic evaluations and toxicological studies

International Journal of Pharmaceutics

Volumn 431, Issue 1-2, 2012, Pages 149-160

  Borhade, Vivek ^a   Pathak, Sulabha ^b   Sharma, Shobhona ^b   Patravale, Vandana ^a  

^a INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^b TATA INSTITUTE OF FUNDAMENTAL RESEARCH   (India)

Author keywords

Clotrimazole; Malaria; Nanoemulsion; Plasmodium berghei; Repeated dose toxicity; Stability

Indexed keywords

5' NUCLEOTIDASE; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIMALARIAL AGENT; ASPARTATE AMINOTRANSFERASE; CLOTRIMAZOLE; GLUTAMATE DEHYDROGENASE; GLUTATHIONE TRANSFERASE ALPHA; IDITOL DEHYDROGENASE; LACTATE DEHYDROGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL ACTIVITY; ARTICLE; CHEMOTHERAPY; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG SCREENING; DRUG STABILITY; ENZYME BLOOD LEVEL; FEMALE; GROWTH INHIBITION; IN VIVO STUDY; LIVER TOXICITY; MALE; MOUSE; NANOEMULSION; NONHUMAN; PARASITEMIA; PHARMACODYNAMICS; PLASMODIUM BERGHEI; PLASMODIUM BERGHEI INFECTION; PRIORITY JOURNAL; RAT; REPEATED DRUG DOSE; SURVIVAL; SUSPENSION;

EID: 84863411109     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2022.121616     Document Type: Erratum

References (47)

1. K. Bangchang, and J. Karbwang Current status of malaria chemotherapy and the role of pharmacology in antimalarial drug research and development Fund. Clin. Pharmacol. 23 2009 387 409
2. J.E. Bennett Chemotherapy of systemic mycoses (second of two parts) N. Engl. J. Med. 290 1974 320 323
3. M. Bonnet, I. Broek, M. Herp, C. Overmeir, J. Kyomuhendo, C.N. Ndosimao, E. Ashley, and J.P. Guthmann Varying efficacy of artesunate-amodiaquine and artesunate-sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in the Democratic Republic of Congo: a report of two in vivo studies Malar. J. 8 2009 192 201
4. V.B. Borhade, H.A. Nair, and D.D. Hegde Design and evaluation of self-microemulsifying drug delivery system (SMEDDS) of tacrolimus AAPS PharmSciTech. 9 2008 13 21
5. + channel: the imidazole ring is not required for inhibitory activity J. Pharmacol. Exp. Ther. 273 1995 266 272
6. C. Brugnara, B. Gee, C.C. Armsby, S. Kurth, N. Rifai, S.L. Alper, and O.S. Platt Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease J. Clin. Invest. 97 1996 1227 1234
7. S. Budavari Clotrimazole S. Budavari, The Merck Index 11th edition 1989 Merck and Co., Inc. NJ, USA 2412
8. M.A. Burgess, and G.P. Bodey Clotrimazole (Bay b 5097): in vitro and clinical pharmacological studies Antimicrob. Agents Chemother. 2 1972 423 426
9. W.B. Dennison, R.F. Loeser, R.A. Turner, J.A. Johnson, and H.B. Wells A double blind placebo controlled trial of low dose clotrimazole in rheumatoid arthritis J. Rheumatol. 17 1990 1003 1007
10. A.M. Dondorp, F. Nosten, P. Yi, D. Das, A.P. Phyo, K.M. Lwin, F. Ariey, W. Hanpithakpong, S.J. Lee, K. Silamut, M. Imwong, K. Chotivanich, P. Lim, T. Herdman, S. Yeung, P. Singhasivanon, N.P. Day, N. Lindegardh, D. Socheat, and N.J. White Artemisinin resistance in Plasmodium falciparum malaria N. Engl. J. Med. 361 2009 455 467
11. D.A. Fidock, P.J. Rosenthal, S.L. Croft, R. Brun, and S. Nwaka Antimalarial drug discovery: efficacy models for compound screening Nat. Rev. Drug Discov. 3 2004 509 520
12. L.Y. Galichet Clotrimazole A.C. Moffat, M.D. Osselton, B. Widdop, Clarke's Analysis of Drugs and Poisons third edition 2003 Pharmaceutical Press London, UK (Electronic Version)
13. F.J. Gamo, L.M. Sanz, J. Vidal, C. Cozar, E. Alvarez, J. Lavandera, D.E. Vanderwall, D.V.S. Green, J.R. Brown, C.E. Peishoff, L.R. Cardon, and B.J.F. Garcia Thousands of chemical starting points for antimalarial lead identification Nature 465 2010 305 312
14. F. Gao, Z. Zhang, H. Bu, Y. Huang, Z. Gao, J. Shen, C. Zhao, and Y. Li Nanoemulsion improves the oral absorption of candesartan cilexetil in rats: performance and mechanism J. Control. Release 149 2009 168 174
15. M.H. Gelb Drug discovery for malaria: a very challenging and timely endeavor Curr. Opin. Chem. Biol. 11 2007 440 445
16. S. Gemma, G. Campiani, S. Butini, G. Kukreja, S.S. Coccone, B.P. Joshi, M. Persico, V. Nacci, I. Fiorini, E. Novellino, E. Fattorusso, O.T. Scafati, L. Savini, D. Taramelli, N. Basilico, S. Parapini, G. Morace, V. Yardley, S. Croft, M. Coletta, S. Marini, and C. Fattorusso Clotrimazole scaffold as an innovative pharmacophore towards potent antimalarial agents: design, synthesis, and biological and structure-activity relationship studies J. Med. Chem. 51 2008 1278 1294
17. J.M. Higgs The use of clotrimazole in the treatment of chronic mucocutaneous candidiasis Postgrad. Med. J. 50 Suppl. 1 1974 57
18. R.J. Holt, and R.L. Newman Laboratory assessment of the antimycotic drug clotrimazole J. Clin. Pathol. 25 1972 1089 1097
19. R.J. Holt Laboratory and clinical studies with clotrimazole Postgrad. Med. J. 50 Suppl. 1 1974 24 27
20. N.T. Huy, K. Kamei, T. Yamamoto, Y. Kondo, K. Kanaori, R. Takano, K. Tajima, and S. Hara Clotrimazole binds to heme and enhances heme-dependent hemolysis J. Biol. Chem. 277 2002 4152 4158
21. ICH, International conference on harmonization of technical requirements for registration of pharmaceuticals for human use. Validation of analytical procedures: text and methodology Q2(R1), Geneva, Switzerland, November 2005.
22. ICH, International conference on harmonization of technical requirements for registration of pharmaceuticals for human use. Impurities in new drug products, Q3B(R2), Geneva, Switzerland, 2006.
23. ICH, International conference on harmonization of technical requirements for registration of pharmaceuticals for human use. Stability testing of new drug substances and products, Q1A (R2), Geneva, Switzerland, February 2003.
24. M.M. Ipp, L. Boxall, and E.W. Gelfand Clotrimazole intermittent therapy in chronic mucocutaneous candidiasis Am. J. Dis. Child 131 1977 305 307
25. W. Marget, and D. Adam BAY B 5097, a new orally applicable antifungal substance with broad spectrum activity. Preliminary clinical and laboratory experience in children Acta Paediat. Scand. 60 1971 341
26. R.H. Meade Treatment of chronic mucocutaneous candidiasis Ann. Intern. Med. 86 1977 314 316
27. P. Olliaro, and T.N.C. Wells The global portfolio of new antimalarial medicines under development Clin. Pharmacol. Ther. 85 2009 584 595
28. T.S. Osdene, P.B. Russell, and L. Rane 2,4,7-Triamino-6-orthosubstituted arylpteridines. A new series of potent antimalarial agents J. Med. Chem. 10 1967 431 436
29. M. Pedersen Effect of hydrotropic substances on the complexation of clotrimazole with β-cyclodextrin Drug Dev. Ind. Pharm. 19 1993 439 448
30. W. Peters, and B.L. Robinson Malaria O. Zak, M. Sande, Handbook of Animal Models of Infection 1999 Academic Press London, UK 757 773 (Chapter 92)
31. C.J.H. Porter, C.W. Pouton, J.F. Cuine, and W.N. Charman Enhancing intestinal drug solubilisation using lipid-based delivery systems Adv. Drug Deliv. Rev. 60 2008 673 691
32. C.W. Pouton, and C.J.H. Porter Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies Adv. Drug Deliv. Rev. 60 2008 625 637
33. N. Rifai, M. Sakamoto, T. Law, O. Platt, M. Mikati, C.C. Armsby, and C. Brugnara HPLC measurement, blood distribution, and pharmacokinetics of oral clotrimazole, potentially useful antisickling agent Clin. Chem. 41 1995 387 391
34. J.S. Saliba, and K. Kirk Clotrimazole inhibits the growth of Plasmodium falciparum in vitro Trans. R. Soc. Trop. Med. Hyg. 92 1998 666 667
35. P.R. Sawyer, R.N. Brogden, R.M. Pinder, T.M. Speight, and G.S. Avery Clotrimazole: a review of its antifungal activity and therapeutic efficacy Drugs 9 1975 424 447
36. S. Shadomy In vitro antifungal activity of clotrimazole (Bay b 5097) Infect. Immun. 4 1971 143 149
37. D. Tettenborn Toxicity of clotrimazole Postgrad. Med. J. 50 Suppl. 1 1974 17 20
38. T. Tiffert, H. Ginsburg, M. Krugliak, B.C. Elford, and V.L. Lew Potent antimalarial activity of clotrimazole in in vitro cultures of Plasmodium falciparum Proc. Natl. Acad. Sci. U.S.A. 97 2000 331 336
39. USP Convention Clotrimazole The Official Compendia of Standards: The United States Pharmacopeia 2007 USP 30 NF 25 Rockville, USA
40. J.A. Waitz, E.L. Moss, and M.J. Weinstein Chemotherapeutic evaluation of clotrimazole (Bay b 5097, 1 (O-chloro-α-α-diphenylbenzyl) imidazole) Appl. Microbiol. 22 1971 891 898
41. L. Weingartner, U. Sitka, R. Patsch, and C. Grundig Studies on the activity of a new antimycotic in children Int. J. Clin. Pharmacol. 6 1972 358 363
42. H. Weuta Clinical studies with oral clotrimazole Postgrad. Med. J 50 1974 45 48
43. N.J. White Assessment of the pharmacodynamic properties of antimalarial drugs in vivo Antimicrob. Agents Chemother. 41 1997 1413 1422
44. N. White Antimalarial drug resistance and combination chemotherapy Philos. Trans. R. Soc. Lond. B: Biol. Sci. 354 1999 739 749
45. WHO. Guidelines for the treatment of malaria. Second edition. Access on 20 March 2010. http://whqlibdoc.who.int/publications/2010/9789241547925-eng.pdf.
46. a Values for some drugs and miscellaneous organic acids and bases D.A. Williams, T.L. Lemke, Foye's Principles of Medicinal Chemistry 2002 Lippincott Williams and Wilkins Philadelphia, USA 1070 1080
47. Y.M. Yin, F.D. Cui, C.F. Mu, M.K. Choi, J.S. Kim, S.J. Chung, C.K. Shim, and D.D. Kim Docetaxel microemulsion for enhanced oral bioavailability: preparation and in vitro and in vivo evaluation J. Control. Release 140 2009 86 94